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Abstract
Background To study the diagnostic and therapeutic fea-
tures of pituitary tumorous hyperplasia due to primary
hypothyroidism.
Methods Fifteen patients with pituitary tumorous hyperplasia
were studied in clinical manifestation, pathologic, endocrino-
logical, radiographic and therapeutic features retrospectively.
Results All of these patients suffered from primary hypo-
thyroidism. Magnetic resonance imaging (MRI) scanning
found that there were masses in the sellar region with equal
T1 and little longer T2 signal, and which could be obviously
enhanced by gadolinium EDTA injection. Diameters of
these masses were between 1.1 and 2.5 cm. Thyroxine
substitution therapy was ordered. Four months later, MRI
scanning found that the masses disappeared and only normal
pituitary gland left. Plasma thyroxine, thyroid-stimulating
hormone (TSH), and prolactin (PRL) levels dropped to their
normal ranges.
Conclusions Thyroxine substitution therapy was the first
choice of pituitary tumorous hyperplasia due to primary
hypothyroidism. If they are followed by TSH adenoma, or
the optic chiasma was pressed by the enlarged pituitary,
transsphenoidal microsurgery could be applied.
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Pituitary tumorous hyperplasia due to primary hypothy-
roidism refers to the enlargement of relevant pituitary-
hormone secreting cells, caused by primary target gland
hypofunction [1, 8]. Pituitary tumorous hyperplasia due
to primary hypothyroidism occurs most frequently
among all feedback tumors, occupying 33.3% [3]. Clin-
ical doctors always pay little attention to it, because it
can not be differentiated easily from primary thyrotropic
adenoma by radiographic features only. However, the
therapeutic principles to treat them are completely dif-
ferent, and clinical doctors frequently misdiagnose it
and order erroneous treatment. From January 1999 to
January 2006, 15 patients with pituitary tumorous hy-
perplasia due to primary hypothyroidism were hospital-
ized in our department. The clinical manifestation,
pathologic, endocrinological, radiographic and therapeu-
tic features of these cases were studied, analysed and
summarized in this paper.
Clinical data
General data
There were 15 patients in total with pituitary tumorous
hyperplasia due to primary hypothyroidism treated in our
department form January 1999 to January 2006. Six of them
were males, nine of them were females. The ages of these
patients were between 13 and 46 years old (average, 24 years
old). The time course of the disease was between 5 months
to 3 years (average, 8 months).
Clinical symptoms
All of the 15 patients had longitudinal symptoms of hypothy-
roidism, such as acratia, aversion to cold, anorexia, facial
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edema, pretibial myxedema and so on. Three of them, who
were younger than 16 years old, had symptoms of hypoevo-
lutism, including growth stasis, microsoma, and hypogonad-
ism. Seven adult female patients had symptoms of amenorrhea
and three of them also had symptoms of lactorrhea.
Results of laboratory examination
All of the 15 patients had different degrees of hormone
disorders. The plasma thyroxines (FT3, FT4) of these
patients were below the normal levels. Plasma thyroid-
stimulating hormone (TSH) levels in these patients were
between 85 and 190 μIU/ml (normal range, 0.38–
4.34 μIU/ml), and prolactin (PRL) was between 50.46 and
180.75 ng/ml (normal range, 3.34–26.72 ng/ml). Other
pituitary-secreting hormones (GH, ACTH) were in the nor-
mal ranges. The concentrations of plasma TG-Ab and TPO-
Ab were found to be raised in 11 patients and remained
normal in the other four patients. Thirteen of the patients
were positive for TMAb.
Laboratory dynamic examination
The results of thyroid-releasing hormone (TRH) stimulation
tests showed enhanced levels in all 15 patients, and the
results of TSH stimulation tests were all decreased in these
patients.
Imaging features
99Tc-nuclide scan was carried out for six patients, which
showed heterogeneous absorption decrease. Thyroid color
ultrasonography found decreased resonance in six patients,
and diffuse heterogeneous resonance in nine patients. Mag-
netic resonance imaging (MRI) scans were undertaken for
15 patients, and computed tomography (CT) scans for five
patients. They all showed a space-occupying mass in the
sellar region. The CT scans found an enlarged pituitary,
promontory of the superior border, collapse of the saddle
floor, thickness and deflection of the pituitary stalk, etc. The
MRI scans found a mass in the sellar region with equal T1
and little longer T2 signal, and the mass could be obviously
enhanced with Gd-EDTA injection. The diameters of these
masses were between 1.1 to 2.5 cm, and some of them grew
upward to the suprasellar region and pressed the optic chi-
asma (Fig. 1a–d).
Results
All of these hospitalized patients were diagnosed to have
primary hypothyroidism according to clinical symptoms,
laboratory examinations, laboratory dynamic hormone-
secreting examination, and thyroid radiographic examina-
tion. The changes in pituitary radiographic features suggested
pituitary tumorous hyperplasia due to primary hypothyroid-
ism. All of them were given 80–120 mg thyroid tablets for
substitute therapy from low dose to cure dose gradually. The
clinical manifestations of hypothyroidism, such as acratia,
intolerance of cold, anorexia, facial edema and so on, were
relieved obviously. Menstruates in seven patients with amen-
orrhea and lactorrhea returned to normal cycle. The symptoms
of the three with development disorders also were obviously
relieved. These patients got more than a 5-cm increase in body
height, and return of male genital development or function.
Plasma T3, T4, TSH and PRL in these patients returned to the
normal range about 30–120 days after therapy (average
85 days). After 4–11 months of substitute therapy, MRI scan
found that the enlarged pituitary in these patients returned to
normal size (Fig. 1e, f).
Discussion
Pituitary tumorous hyperplasia due to hypothyroidism is
defined by obvious enlargement of the pituitary follicle,
hyperplasia of endocrine cells, and changes of pituitary
structure. The differences in ultrastructure between hyper-
plasia cells and normal pituitary cells are very obvious.
These are always caused by pathological factors, and these
are mostly found in primary hypothyroidism [8].
Primary hypothyroidism is often caused by chronic lym-
phocytic thyroiditis (also known as autoimmune thyroiditis
and Hashimoto’s thyroiditis) [6]. Chronic lymphocytic thy-
roiditis usually has a deferment disease course with insidi-
ous clinical signs and symptoms, and can not be diagnosed
and treated timely. Thyroid tissues are infiltrated by multiple
lymphocytes and plasma cells in the early stage of chronic
lymphocytic thyroiditis, and then the follicular structures are
damaged continuously. Dysfunction of thyroid hormone
synthesis and secretion appears later. The reduced concen-
tration of serum FT3 and FT4 causes weakness of inhibition
to hypothalamus TRH secretion and pituitary TSH secretion
through a long loop feedback modulation mechanism, and
then the hypothalamus TRH secretion increases, followed
by hyperplasia and hypertrophy of pituitary TSH-secreting
cells and degeneration of basophilic cells. All of these
changes lead to enlargement of anterior pituitary and some-
times adenoma. The increased hypothalamus TRH secretion
could not only lead to hyperplasia and hypertrophy of pitu-
itary TSH-secreting cells and increased secretion of TSH but
also stimulate PRL-secreting cells, promote PRL synthesis
and secretion. Thereby, raised serum PRL level and hyper-
prolactinemia appear.
Pituitary tumorous hyperplasia due to primary hypothy-
roidism could not be easily differentiated from primary TSH
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adenoma, only by radiographic features. But the treatment is
obviously different. For primary TSH adenoma, microsurgical
treatment is preferred; but for pituitary tumorous hyperplasia
due to primary hypothyroidism, thyroxine replacement thera-
py is preferred [7]. In patients suffering from primary TSH
adenoma, symptoms like various degrees of hyperthyroidism
and goitre, an increase of serum FT3, FT4, and TSH could be
found; but the serum thyroid antibodywas negative. However,
in patients suffering from pituitary tumorous hyperplasia due
to hypothyroidism, decreased serum FT3 and FT4, elevated
TSH level can be found. Also, TRH stimulation test showed
active results. Sometimes various degrees of hyperprolactine-
mia could be found.
Substitute therapy is the most important treatment for
hypothyroidism [4, 5]. Ozbey et al. [4] once reported the
case of a patient suffering from a large pituitary adenoma
(which confirmed by pituitary MRI scan) secondary to
primary hypothyroidism, hyperprolactinemia and amenor-
rhea. After treatment with L-T4, plasma T3, T4, TSH, PRL
and menstruation returned to their normal ranges, and the
large pituitary adenoma disappeared in MRI scan. This
prompted that the large pituitary adenoma was caused by
the hyperplasia and hypertrophy of TSH and PRL secreting
cells. So we could think that thyroxine was the more pre-
ferred treatment for patients suffered of primary hypothy-
roidism with hyperprolactinemia and pituitary enlargement
Fig. 1 a, b MRI coronal scan
showing pituitary enlargement
with equal T1 signal, close to
the optic chiasm. c, dMRI scan
showing a pituitary mass
obviously and uniformly
enhanced by Gd-EDTA
injection. e and f MRI coronal,
sagittal scan showing pituitary
size return to normal size after
taking thyroxine tablets
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prior to surgery and bromocriptine. Thyroxine substitute
treatment showed significant clinical therapeutic effect.
The time course of treatment should be more than
4 months and sometimes must be more than 2 years.
And if necessary, some patients may need to take the
medicine for life. The dosage of thyroxine should begin
with a low dose (20–30 mg per day), and increase to
maintenance dose gradually every 2–3 weeks. Serum T3,
T4, TSH level should be tested regularly during the
course of therapy, the dose of thyroxine should be adjust-
ed according to the results, and the treatment should not
be stopped, even encountering pregnancy. In this group,
all of these patients received substitute thyroxine therapy
for 4 months, and then the serum T3, T4, and TSH of
these patients returned to their normal ranges. In female
patients, menstruation returned and lactorrhea stopped.
MRI scan showed intrasellar pituitary “adenoma” shrunk
significantly. All of these changes confirmed that the
symptoms of lactorrhea, amenorrhea, and pituitary en-
largement were attributable to primary hypothyroidism.
Three months after substitute therapy, the repeated test
of serum T3, T4, and TSH should be carried out. If the
results show that TSH level declined partially, but the
thyroid function made no significant improvement, long-
term increased secretion of anterior pituitary TSH-
secreting cells should be considered [2]; and this may
lead to the formation of adenoma on the basis of TSH-
secreting cell hyperplasia. If this happened, microsurgical
resection via a transsphenoidal approach could be or-
dered. If the optic nerve or optic chiasm were pressed
by the adenoma, microsurgery should be chosen first, to
relieve the pressure, and thyroxine tablet substitute thera-
py should be taken after surgery. If after more than 4–
6 months of thyroxine tablet substitute therapy, serum
TSH level declined but serum PRL level remained high,
and amenorrhea and lactorrhea continued, while enlarged
pituitary did not shrink in MRI scan, in this case, we
should consider whether there is a pituitary PRL adenoma
or not.
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Comment
This is an impressive series of 15 patients with myxodematous thyro-
troph hyperplasia. The first report of this condition which I am aware
of was important enough to be published in Lancet in 1987 [1].
It can easily be missed if surgeons (and sometimes endocrinolo-
gists) are not vigilant in checking hormone function—high TSH and
low T4 gives it away.
As stated, first-line treatment is thyroxine as surgery is not helpful
and even medical treatment for visual loss leads to rapid recovery.
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